摘要
目的观察急性时相血清淀粉样蛋白A(A-SAA)和罗格列酮(RGZ)对内皮细胞白细胞介素(IL)6和IL-8基因表达的影响。方法分别用不同浓度(0.5μg/ml、5μg/ml)的A-SAA、RGZ(10μmol/L)处理ECV304内皮细胞8h、24h后抽提总RNA,用RT-PCR技术检测IL-6、IL-8 mRNA的表达。结果 A-SAA能显著促进ECV304细胞IL-6、IL-8 mRNA的表达,并呈剂量和时效依赖性(P<0.01)。而RGZ并不影响A-SAA对ECV304细胞IL-6和IL-8 mRNA表达的促进作用。结论 A-SAA可通过促进内皮细胞IL-6、IL-8的表达和分泌,参与动脉粥样硬化的形成;RGZ并非通过影响A-SAA对内皮细胞IL-6和IL-8表达的促进作用发挥其抗炎、抗动脉粥样硬化的作用。
Objective To observe the effects of acute phase serum amyloid protein A(A-SAA) and rosiglitazone on the expressions of interleukin (IL)-6 and-8 in endothelial cells. Methods Total RNA of ECV304 endothelial cells incubated with 0. 5μg/ml, 5μg/ml A-SAA and rosiglitazone (10/μmol/L) for 8 hours or 24 hours was isolated by TRIZOL method. Semi-quantitative RT-PCR was performed to quantitate the expressions of IL-6 and IL-8. Results A-SAA induced IL-6, IL-8 mRNA expressions in ECV304 endothelial cells (P〈0.01), and the results showed that the A-SAA induced-expressions of IL- 6, IL-8 mRNA were dose-dependent and time-dependent. PPAR activator rosiglitazone didn't influence the A-SAA induction of the expressions of IL-6 and IL-8. Conclusions A-SAA is a new proinflammatory adipokine and has atherogenic effects. A-SAA increases IL-6 and IL-8 gene expressions,which may contribute to insulin resistance and cardiovascular complications.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2009年第7期525-528,共4页
Chinese Journal of Diabetes
基金
国家自然科学基金(30671004)
江苏省自然科学基金(BS2006006)资助项目